Search results for "Tolerability"

showing 10 items of 372 documents

Long-term interferon-α treatment of children with chronic hepatitis delta: A multicentre study

1996

We assessed the efficacy of prolonged interferon-alpha (IFN) therapy in children with chronic hepatitis caused by hepatitis delta virus (HDV) by treating 26 paediatric cases with IFN-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 (medium-term group MTG) or 24 months (long-term group, LTG). Compliance and tolerability were acceptable. At the end of therapy a complete biochemical response [normalization of alanine aminotransferase (ALT)] occurred in 12 children (5/13 in MTG and 7/13 in LTG). A relapse occurred after stopping IFN in 10 cases (five in MTG and five in LTG). Two patients from the LTG had normal liver function tests during 12 months of follow-up. Six of the eight hepa…

Malemedicine.medical_specialtyHepatitis B virusAdolescentmedicine.disease_causeGastroenterologyAntiviral AgentsVirusAntigenChronic hepatitisVirologyInternal medicinemedicineHumansHepatitis B e AntigensChildAntigens ViralHepatitisHepatitis B virusHepatologybusiness.industryInterferon-alphaAlanine Transaminasemedicine.diseaseHepatitis DRecombinant ProteinsClinical trialInfectious DiseasesHBeAgTolerabilityImmunologyChronic DiseaseDNA ViralInterferon Type IPatient ComplianceRNA ViralFemaleHepatitis Delta Virusbusiness
researchProduct

Cognitive profile in BECTS treated with levetiracetam: A 2-year follow-up

2019

Introduction: Benign epilepsy with centrotemporal spikes (BECTS) is a common epileptic syndrome in childhood, characterized by brief and infrequent partial motor seizures, with or without generalization and mostly recurring during sleep. Because of its favorable efficacy, tolerability, and safety profile, levetiracetam (LEV) monotherapy is often administered in these patients. Long-term effects of LEV therapy and its influence on cognitive functions remain controversial.Purpose: This evaluated the changes in the cognitive profile of children with BECTS treated with LEV monotherapy for 2 years, compared with a control group of children with specific learning disabilities.Method: Our patient …

Malemedicine.medical_specialtyLevetiracetamAdolescentBECTSCognitive profileElectroencephalographyAudiologyRolandic03 medical and health sciencesBehavioral NeuroscienceEpilepsyCognition0302 clinical medicineBECTS; Cognitive profile; LevetiracetamHumansMedicine030212 general & internal medicineChildRetrospective StudiesWechsler Intelligence Scale for ChildrenEpilepsymedicine.diagnostic_testbusiness.industryWorking memoryWechsler ScalesElectroencephalographyCognitionmedicine.diseaseEpilepsy RolandicNeurologyTolerabilityCase-Control StudiesCohortAnticonvulsantsFemaleNeurology (clinical)Levetiracetambusiness030217 neurology & neurosurgeryFollow-Up Studiesmedicine.drugEpilepsy & Behavior
researchProduct

Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis

2020

Recent publications showed that circulating neurofilaments (Nfs) may be used as a diagnostic biomarker distinguishing amyotrophic lateral sclerosis (ALS) from ALS mimics with high sensitivity and specificity.1–3 Furthermore, it has been shown that patients with higher Nf levels show faster disease progression1 and shorter survival.2 3 Nf levels remain rather stable during the course of disease.2 Current literature suggests that the diagnostic value of neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains in cerebrospinal fluid is about equal, whereas in blood NfL seems to be superior.4 In this study, we investigated the effect of a high-caloric fatty diet (HCFD) on …

Malemedicine.medical_specialtyNeurofilament[SDV]Life Sciences [q-bio]blood [Neurofilament Proteins]PlaceboDiet High-FatGastroenterology03 medical and health sciencesblood [Amyotrophic Lateral Sclerosis]0302 clinical medicineNeurofilament ProteinsInternal medicinePost-hoc analysismedicineHumansddc:610Amyotrophic lateral sclerosisMESH: Neurofilament ProteinsComputingMilieux_MISCELLANEOUSMESH: Amyotrophic Lateral SclerosisRandomized Controlled Trials as TopicMESH: HumansMESH: Middle Agedbusiness.industryTherapeutic effectAmyotrophic Lateral SclerosisMiddle Agedmedicine.diseaseMESH: Male3. Good healthRiluzole[SDV] Life Sciences [q-bio]Psychiatry and Mental healthMESH: Diet High-FatMESH: Randomized Controlled Trials as TopicTolerabilitystatistics & numerical data [Randomized Controlled Trials as Topic]motor neuron diseasePopulation studySurgeryFemaleNeurology (clinical)businessMESH: Female030217 neurology & neurosurgerymedicine.drug
researchProduct

High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients.

2008

Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized. Diuretics are commonly employed and may show some benefit, but there are insufficient clinical trial data to draw useful conclusions about their clinical use. The aim of this prospective study was to evaluate the efficacy and tolerability of high-dose furosemide and small-volume hypertonic saline solution infusion in reducing leg edema in patients with advanced cancer treated unsuccessfully with diuretics. A prospective study was performed in a consecutive sample of 24 patients admitted to a pain relief and palliative care unit over a period of 18 months. To be eligible to enter the t…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentPeripheral edemaFurosemideEdemaNeoplasmsmedicineEdemaHumansLongitudinal StudiesProspective StudiesDiureticsInfusions IntravenousSalineGeneral NursingAgedAged 80 and overSaline Solution HypertonicLegbusiness.industryFurosemideMiddle AgedHypertonic salineSurgeryAnesthesiology and Pain MedicineTolerabilityAnesthesiaFemaleNeurology (clinical)medicine.symptomDiureticbusinessmedicine.drugJournal of pain and symptom management
researchProduct

Does concomitant diabetes affect treatment responses in overactive bladder patients?

2013

Summary Aims To compare the efficacy and tolerability of a muscarinic receptor antagonist, darifenacin, in the treatment of overactive bladder (OAB) patients with concomitant diabetes as compared with those without comorbidities. Methods Post hoc exploratory analysis of a published, large, non-interventional study in OAB patients treated with darifenacin including 532 diabetics and 1315 controls. Associations of diabetes with treatment responses were evaluated by multiple regression models. Results Diabetics (largely type 2 patients) and controls differed in baseline age, body weight, duration of OAB symptoms and presence of comedications. However, they exhibited similar OAB symptom episode…

Malemedicine.medical_specialtyPyrrolidinesMuscarinic Antagonistsurologic and male genital diseasesAffect (psychology)Diabetes ComplicationsDiabetes mellitusInternal medicineMuscarinic acetylcholine receptorDarifenacinMedicineHumansBenzofuransDose-Response Relationship Drugbusiness.industryUrinary Bladder OveractiveAntagonistUrinary Bladder DiseasesGeneral MedicineMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsEndocrinologyTreatment OutcomeUrinary IncontinenceTolerabilityOveractive bladderConcomitantRegression AnalysisFemaleNocturiabusinessmedicine.drugInternational journal of clinical practice
researchProduct

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm,…

2013

Summary Background Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease. Methods We did a single-arm, open-label, phase 3 study of lomitapide for treatment of patients with homozygous familial hypercholesterolemia. Current lipid lowering therapy was maintained from 6 weeks before baseline through to at least week 26. Lomitapide dose was escalated on the basis of safety and tolerability from 5 mg to a maximum of 60 mg a day. The primary endpoint was mean percent change in levels of LDL cholesterol from baseline …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaMipomersenPhases of clinical researchSocio-culturaleFamilial hypercholesterolemialdl-apheresismtp inhibitorBenzimidazoleMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundlipid lowering therapyInternal medicineClinical endpointMedicinelomitapidebiologybusiness.industryCholesterolMedicine (all)Homozygotelomitapide; ldl-apheresis; lipid lowering therapy; homozygous familial hypercholesterolemia; mtp inhibitorGeneral MedicineCholesterol LDLhomozygous familial hypercholesterolemiamedicine.diseaseLomitapideEndocrinologyTolerabilitychemistrybiology.proteinFemalebusinessCarrier ProteinHuman
researchProduct

Comparative responses to three different types of interferon-α in patients with chronic hepatitis C

1999

We investigated the efficacy and tolerability of three different types of interferon-alpha, administered with the same schedule to naive patients with chronic hepatitis C. One hundred and seven patients with histologically proven chronic hepatitis C were enrolled during a period of three years and randomly divided into three groups, to receive (a) leukocyte-interferon-alpha, 6 MU three times a week for 4 months, followed by 3 MU three times a week for 8 months (Group I); (b) recombinant-IFN-alpha-2a, with the same schedule (Group II); and (c) lymphoblastoid-IFN-alpha-N1, with the same schedule (Group III). All patients were followed-up for 6 months to evaluate the long-term response. The 'C…

Malemedicine.medical_specialtyTime FactorsCirrhosisAlpha interferonGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicinemedicineHumansAdverse effectAgedAnalysis of Variancebusiness.industryBiopsy NeedleRemission InductionInterferon-alphaGamma globulinGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsLiverTolerabilityInterferon Type IImmunologyFemaleAnalysis of variancebusiness
researchProduct

A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy.

2015

Objective: To compare the effectiveness of controlled-released carbamazepine (CR-CBZ) to levetiracetam (LEV) and to lamotrigine (LTG) in elderly patients with newlydiagnosedfocalepilepsy.Methods: Randomized, double-blind, parallel-group trial conducted between January2007andAugust2011,in47ambulatoryorhospitalsitesinGermany,Austria,orSwit-zerland. Eligible participants were aged ≥60, had new-onset epilepsy, had no acute ill-nessasthecauseoftheirseizures,andhadnocontraindicationtothedrugsinthetrial.Patients were randomized 1:1:1 to CR-CBZ, LTG, or LEV. Doses were up-titrated for6 weeks and could be maintained or adjusted depending on seizure relapse or tolera-bility over an additional period …

Malemedicine.medical_specialtyTime FactorsPopulationKaplan-Meier EstimateLamotrigineEpilepsyDouble-Blind MethodInternal medicinemedicineHumansLongitudinal StudiesAdverse effecteducationAgedRetrospective Studieseducation.field_of_studyDose-Response Relationship Drugbusiness.industryCarbamazepineMiddle Agedmedicine.diseaseDiscontinuationEuropeLogistic ModelsTreatment OutcomeNeurologyTolerabilityAnesthesiaAnticonvulsantsFemaleNeurology (clinical)LevetiracetamEpilepsies Partialbusinessmedicine.drugEpilepsia
researchProduct

Does Transfer Capacitive Resistive Energy Has a Therapeutic Effect on Peyronie's Disease? Randomized, Single-Blind, Sham-Controlled Study on 96 Patie…

2017

<b><i>Background/Aims/Objectives:</i></b> We have investigated the clinical and physiological effects of Transfer Capacitive Resistive Energy (TCARE) therapy on men with Peyronie's disease (PD). <b><i>Methods:</i></b> Ninety-six men with PD have been randomized in a 2:1 ratio to receive 3 sessions of TCARE therapy or sham therapy. Pain, penile curvature and erectile function have been assessed before the first treatment and up to 9 months after the end of treatment, using the Visual Analogue Scale for the pain, a goniometer to measure the degree of curvature using at-home photography and an International Index of Erectile Function (IIEF-5) que…

Malemedicine.medical_specialtyTime FactorsVisual analogue scalePeyronie's diseaseUrologyPenile Induration030232 urology & nephrologyPain reliefPainElectric Stimulation TherapyElectric Capacitance03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesElectric ImpedanceMedicineHumansSingle-Blind MethodAdverse effectPenile painAgedPain MeasurementResistive touchscreenErectile failure; Induratio penis plastic; Penile pain; Penis plaque; Peyronie's disease; Transfer capacitive resistive energy; Urology030219 obstetrics & reproductive medicinebusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaPenile ErectionInduratio penis plasticTransfer capacitive resistive energyTherapeutic effectRecovery of FunctionMiddle Agedmedicine.diseaseTreatment OutcomeTolerabilityItalyPhysical therapyPenile painPeyronie's diseasebusinessErectile failurePenis plaquePenisUrologia internationalis
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct